Janssen

DARZALEX

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Janssen

Darzalex HCPCS:

J9145

HCPCS Code Descriptor:

Injection, daratumumab, 10 mg

Category:

J Code

Darzalex NDCs:

57894-0505-05, 57894-0502-05, 57894-0502-20, 57894-0505-20

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Darzalex CPT Codes:

Potential CPT administration codes for Darzalex can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Darzalex:

DARZALEX is an Oncology drug manufactured by Janssen and administered via the Intravenous route of administration. The J Code: J9145 is aligned to the drug DARZALEX.

Darzalex is a drug that is indicated for the treatment of multiple myeloma, a type of cancer of the white blood cells. Darzalex is thought to work by blocking a specific protein on myeloma cells called CD38. This is thought to help reduce the cancer's ability to grow. Datzalex is administered as an infusion and is often combined with other forms of treatment.

ACCESS PRICING AND MORE BY REGISTERING

J9145 Added Date:

January 1, 2017

J9145 Effective Date:

January 1, 2017

J9145 Termination Date:

HCPCS Active

Darzalex billing and coding information can be found through Janssen at the link below:
Darzalex patient assistance information can be found through the Johnson and Johnson Patient Assistance Foundation at the URL: http://www.jjpaf.org/
DARZALEX prescribing information can be found at the link below:
Information regarding DARZALEX’s side effects can be found at MedlinePlus